Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Sees Large Increase in Short Interest

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRFGet Free Report) (TSE:CPH) was the target of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 25,400 shares, a growth of 43.5% from the May 15th total of 17,700 shares. Based on an average daily trading volume, of 19,000 shares, the short-interest ratio is presently 1.3 days.

Cipher Pharmaceuticals Trading Up 0.6 %

Shares of OTCMKTS:CPHRF traded up $0.04 on Friday, hitting $6.23. 4,344 shares of the company were exchanged, compared to its average volume of 15,779. The stock’s 50 day moving average price is $6.45 and its 200 day moving average price is $5.54. Cipher Pharmaceuticals has a 1-year low of $2.50 and a 1-year high of $7.45.

Cipher Pharmaceuticals Company Profile

(Get Free Report)

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.

Read More

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with's FREE daily email newsletter.